荟萃分析:炎症性肠病妊娠合并妊娠期肝内胆汁淤积症
该系统评价与荟萃分析检索MEDLINE、EMBASE和EMBASE Classic数据库至2024年9月10日,纳入2篇病例报告、1个8例病例系列和3项队列研究,共1603例炎症性肠病(IBD)妊娠。IBD妊娠中妊娠期肝内胆汁淤积症(ICP)的合并患病率为3%(95%CI 1.0%-7.0%),一项队列研究报告IBD中ICP患病率显著高于一般人群(OR 3.08,95%CI 1.11-8.56,p=0.039)。荟萃分析显示硫嘌呤暴露与ICP风险增加相关(OR 6.65,95%CI 3.10-14.25);一项队列研究显示,与非IBD对照相比,硫嘌呤暴露妊娠的ICP发生率增加(OR 7.55,95%CI 2.52-22.57,p<0.001),而未暴露妊娠无显著增加(OR 1.41,95%CI 0.40-4.92,p=0.75)。
要点
- IBD妊娠中ICP合并患病率为3%(95%CI 1.0%-7.0%)。
- IBD患者ICP患病率显著高于一般人群(OR 3.08,95%CI 1.11-8.56,p=0.039)。
- 硫嘌呤暴露与ICP风险增加相关(OR 6.65,95%CI 3.10-14.25)。
核心结论
- IBD患者发生ICP的风险高于一般人群。
- IBD患者硫嘌呤暴露与ICP风险增加相关。
- 临床医生应监测接受硫嘌呤暴露的IBD妊娠患者是否出现ICP症状。
研究设计与样本
- 电子检索MEDLINE、EMBASE和EMBASE Classic数据库,检索词为IBD和ICP,检索时间从建库至2024年9月10日。
- 纳入经确诊的IBD妊娠成人且报告ICP的研究,共识别2篇病例报告、1个8例病例系列和3项队列研究。
- 采用随机效应模型合并ICP的患病率和事件数。
主要发现
- 1603例IBD妊娠中ICP的合并患病率为3%(95%CI 1.0%-7.0%)。
- 一项队列研究报告IBD中ICP患病率显著高于一般人群(OR 3.08,95%CI 1.11-8.56,p=0.039)。
- 荟萃分析显示硫嘌呤暴露与ICP风险增加相关(OR 6.65,95%CI 3.10-14.25)。
- 一项队列研究显示,与非IBD对照相比,硫嘌呤暴露妊娠的ICP发生率增加(OR 7.55,95%CI 2.52-22.57,p<0.001),而未暴露妊娠无显著增加(OR 1.41,95%CI 0.40-4.92,p=0.75)。
关键数值与推荐
- IBD妊娠中ICP合并患病率3%(95%CI 1.0%-7.0%)。
- IBD vs 一般人群的ICP患病率OR 3.08(95%CI 1.11-8.56,p=0.039)。
- 硫嘌呤暴露与ICP风险OR 6.65(95%CI 3.10-14.25)。
- 硫嘌呤暴露妊娠 vs 非IBD对照的ICP发生率OR 7.55(95%CI 2.52-22.57,p<0.001)。
- 硫嘌呤未暴露妊娠 vs 非IBD对照的ICP发生率OR 1.41(95%CI 0.40-4.92,p=0.75)。
临床怎么用
- 临床医生应监测接受硫嘌呤暴露的IBD妊娠患者是否出现ICP症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory Bowel Disease (IBD) requires maintenance of remission during pregnancy to avoid poor maternal and fetal outcomes. Intrahepatic cholestasis of pregnancy (ICP) could also increase these risks. AIMS: To examine the prevalence of ICP in pregnancies with IBD and associations with thiopurine exposure. METHODS: An electronic search of MEDLINE, EMBASE, and EMBASE Classic databases using search terms for IBD and ICP from inception to 10th September 2024 was performed. Studies involving pregnant adults with a confirmed diagnosis of IBD reporting ICP were included. Prevalence and event numbers for ICP were pooled using a random effects model. RESULTS: We identified two case reports, a case series of eight cases, and three cohort studies. Pooled prevalence of ICP in 1603 pregnancies with IBD was 3% (95% confidence interval [CI] 1.0%-7.0%). One cohort study reported that the prevalence of ICP in IBD was significantly higher compared to the general population (odds ratio [OR] 3.08 [95% CI 1.11-8.56], p = 0.039). Meta-analysis showed that thiopurine exposure was associated with an increased risk of ICP, OR 6.65 [95% CI 3.10-14.25]. One cohort study showed that, compared to non-IBD controls, the incidence of ICP was increased in thiopurine exposed pregnancies (OR 7.55 [95% CI 2.52-22.57] p < 0.001) but not in non-exposed pregnancies (OR 1.41 [95% CI 0.40-4.92], p = 0.75). CONCLUSIONS: Patients with IBD have a higher risk of ICP compared to the general population. Thiopurine exposure in patients with IBD is associated with an increased risk of ICP. Clinicians should monitor pregnant patients with IBD exposed to thiopurines for symptoms of ICP.
引用
- Joudaki S, Oladipupo O, Carbery I, et al. Meta-Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy. Aliment Pharmacol Ther. 2025. PMID: 40114011. doi:10.1111/apt.70096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。